CD274 and cancer: Clinical trials are being conducted to investigate the effects of immune checkpoint inhibitors (ICIs) using PD-1/PD-L1 antibodies as companion diagnostic tools to determine the PD-L1 expression in MPM patients [13–15] in the same way as other malignant tumors.